Literature DB >> 28671249

Mechanism of reversal of multidrug resistance by curcumin in human colorectal cancer cell line HCT-8/5-FU.

Y X Fan1, P Abulimiti1, H L Zhang2, Y K Zhou3, L Zhu3.   

Abstract

Since there are no studies on the reversal of multidrug resistance by curcumin in the human colorectal cancer cell line HCT-8/5-FU, our aim was to search for highly efficient reversal agents and investigate the underlying mechanisms of this reversal. The cytotoxic effects of curcumin and 5-FU on HCT-8 and HCT-8/5-FU cells and the reversal effects of 5-FU in combination with curcumin on HCT-8/5-FU cells were measured using cell counting kit-8. Apoptosis and the cell cycle were analyzed by flow cytometry. Protein and mRNA expression levels of BCL-2, survivin, P-gp, and HSP-27 were detected by western blotting and quantitative real-time reverse transcription polymerase chain reaction, respectively. Curcumin inhibited the growth of HCT-8 and HCT-8/5-FU cells. It significantly reduced the IC50 of 5-FU for HCT-8/5-FU cells (P < 0.01) and the expression of BCL-2, survivin, P-gp, and HSP-27 in the cells. Curcumin can effectively reverse multidrug resistance in human colorectal cancer drug-resistant HCT-8/5-FU cells. The mechanism through which this occurs may be associated with decreased expression of BCL-2, survivin, P-gp, and HSP-27. Curcumin may therefore have clinical implications as a new agent for colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28671249     DOI: 10.4238/gmr16029414

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  2 in total

1.  Role of HSP27 in the multidrug sensitivity and resistance of colon cancer cells.

Authors:  Zhengyong Liu; Yi Liu; Yupeng Long; Baohua Liu; Xiangfeng Wang
Journal:  Oncol Lett       Date:  2020-01-07       Impact factor: 2.967

2.  Nrf2 is a key factor in the reversal effect of curcumin on multidrug resistance in the HCT‑8/5‑Fu human colorectal cancer cell line.

Authors:  Chao Zhang; Lian-Jun He; Hai-Zhu Ye; Ding-Feng Liu; Yi-Bao Zhu; Dong-Dong Miao; Sheng-Peng Zhang; Yun-Yu Chen; Yuan-Wei Jia; Jie Shen; Xiao-Ping Liu
Journal:  Mol Med Rep       Date:  2018-10-24       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.